BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

ame-body">Immuneel, a Bangalore start-up dedicated to making cancer cell therapies available in India at prices far below those charged in developed countries, announced Tuesday its first step to bring CAR T treatments to the subcontinent. Immuneel Therapeutics...
BioCentury | Oct 2, 2020
Product Development

With patient groups’ endorsement, Amylyx, FDA to discuss approval of ALS therapy

...venture-backed biotech a short path to a marketed drug.Two foundations, the ALS Association and I AM...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Warp Speed’s Slaoui expects two COVID-19 vaccines this year, rebuts Sen. Warren

...have a call from the administration. I am...
...GSK, I have never sold shares. I am...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

ame-body">Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

...COVID-19 is not sustainable. “It cannot be done over and over,” said de Rubertis.  “I am...
...COVID will be applied to the infectious disease market and there will be -- I am...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

...Nisa, right? [00:00:23] Nisa Leung: Yup, I am...
BioCentury | Sep 9, 2020
Product Development

McMurry-Heath: COVID-19 raises stakes for industry to take the lead on promoting science: a BioCentury audio interview

...need to tell better. We at the Biotechnology Innovation Organization are trying through our I Am...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...where are you sitting today? You're in the Netherlands? [00:00:22] Jan van de Winkel: I am...
BioCentury | Aug 24, 2020
Politics, Policy & Law

Angered by NIH’s Collins, Trump misfires and hits FDA Commissioner Hahn

...Research (CBER). He also criticized the way it has been presented to the public. “I am...
BioCentury | Aug 11, 2020
Product Development

Charting a path to COVID-19 testing that supports a return to normalcy

...what everyone really wants to know -- am I infectious, will I get sick, and am...
Items per page:
1 - 10 of 1906